SPDR S&P Pharmaceuticals ETF Rating → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free XPH Stock Alerts $41.07 +0.05 (+0.12%) (As of 12:31 PM ET) Add Compare Share Share RatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy2.65Holdings in XPH have an aggregate rating of Moderate Buy based on 297 analyst ratings issued in the past year covering 40 companies (98.9% of the portfolio).XPH Aggregate Price Target$65.7659.93% UpsideHigh Prediction$84.48Average Prediction$65.76Low Prediction$47.24Holdings in XPH have an aggregate price target of $65.76 and a range of $47.24 to $84.48 covering 40 companies (98.9% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy17 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell1 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 40 XPH Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.35%ITCIIntra-Cellular Therapies$66.52+0.3%5 of 5 stars2.90$90.17 35.5%10Earnings ReportAnalyst Revision5.24%MRKMerck & Co., Inc.$128.30-0.8%5 of 5 stars2.58$131.33 2.4%125.13%PRGOPerrigo$30.10-2.3%5 of 5 stars3.00$40.67 35.1%3Gap Down4.96%OGNOrganon & Co.$21.29+1.7%4 of 5 stars2.50$22.60 6.2%44.88%CTLTCatalent$55.74-0.1%3 of 5 stars2.15$52.46 -5.9%13Earnings ReportAnalyst ForecastShort Interest ↓4.78%AXSMAxsome Therapeutics$76.57+1.2%4 of 5 stars2.92$121.92 59.2%134.75%LLYEli Lilly and Company$755.51-0.3%5 of 5 stars2.84$757.95 0.3%19Short Interest ↓4.65%VTRSViatris$11.15-1.8%1 of 5 stars1.33$11.00 -1.3%3Earnings Report4.60%PFEPfizer$28.22-0.8%5 of 5 stars2.40$35.86 27.1%154.59%JAZZJazz Pharmaceuticals$111.27-1.7%5 of 5 stars2.85$192.75 73.2%134.55%RPRXRoyalty Pharma$27.89-1.7%5 of 5 stars3.00$46.75 67.6%4Earnings Report4.52%JNJJohnson & Johnson$150.87-0.2%5 of 5 stars2.46$175.86 16.6%13Short Interest ↑4.29%ZTSZoetis$168.73+0.5%5 of 5 stars3.00$211.75 25.5%7Short Interest ↑4.11%BMYBristol-Myers Squibb$44.62-1.0%5 of 5 stars2.11$60.00 34.5%19Short Interest ↓Analyst Revision3.98%ELANElanco Animal Health$17.15+0.9%3 of 5 stars2.57$18.29 6.6%7Earnings ReportAnalyst ForecastShort Interest ↓Analyst Revision3.45%CORTCorcept Therapeutics$27.520.0%5 of 5 stars3.00$40.10 45.7%4Insider SellingShort Interest ↓2.54%ARVNArvinas$31.52-0.2%2 of 5 stars2.88$61.13 94.0%16Earnings ReportAnalyst Revision2.17%SAVACassava Sciences$22.78+10.5%3 of 5 stars3.00$124.00 444.3%1Gap Up2.17%AMPHAmphastar Pharmaceuticals$42.55+0.4%5 of 5 stars2.50$66.00 55.1%4Analyst Upgrade1.97%EYPTEyePoint Pharmaceuticals$12.77+4.5%3 of 5 stars3.00$33.71 164.0%7Analyst ForecastAnalyst RevisionGap Up1.70%TARSTarsus Pharmaceuticals$38.05-0.8%3 of 5 stars2.88$50.38 32.4%8Analyst ForecastAnalyst Revision1.47%PBHPrestige Consumer Healthcare$71.47+1.4%4 of 5 stars2.50$110.00 53.9%2Analyst Upgrade1.25%PCRXPacira BioSciences$30.94+1.8%5 of 5 stars3.00$47.40 53.2%101.22%LBPHLongboard Pharmaceuticals$20.20+1.4%3 of 5 stars3.00$43.67 116.2%6Short Interest ↓1.18%HRMYHarmony Biosciences$29.60-2.1%4 of 5 stars2.50$40.63 37.2%8Positive News1.15%COLLCollegium Pharmaceutical$32.47+1.0%3 of 5 stars2.20$39.00 20.1%5News Coverage1.00%LQDALiquidia$12.35+1.7%2 of 5 stars2.60$21.00 70.0%5News CoveragePositive News0.91%SUPNSupernus Pharmaceuticals$29.08-2.0%4 of 5 stars3.00$41.00 41.0%10.91%AMLXAmylyx Pharmaceuticals$1.87+2.7%3 of 5 stars2.25$32.67 1,646.9%8Earnings ReportAnalyst ForecastNews Coverage0.86%AMRXAmneal Pharmaceuticals$6.77+0.9%2 of 5 stars3.00$8.25 21.9%4Short Interest ↓0.81%LGNDLigand Pharmaceuticals$85.11+1.2%5 of 5 stars3.00$116.33 36.7%3Earnings ReportInsider Selling0.65%ANIPANI Pharmaceuticals$65.77-2.3%5 of 5 stars3.00$81.00 23.2%4Analyst ForecastNews Coverage0.58%PLRXPliant Therapeutics$13.98+2.3%4 of 5 stars3.00$45.67 226.7%10Gap Up0.57%RVNCRevance Therapeutics$3.50+5.4%4 of 5 stars2.50$11.50 228.6%8Analyst ForecastNews CoverageGap Up0.46%EOLSEvolus$12.71+0.8%4 of 5 stars3.00$20.60 62.1%30.39%TBPHTheravance Biopharma$9.53-0.5%2 of 5 stars3.00$20.50 115.1%2Analyst ForecastNews Coverage0.36%XERSXeris Biopharma$1.91+1.1%4 of 5 stars3.00$4.63 142.1%4Earnings Report0.36%OCULOcular Therapeutix$6.09+8.0%3 of 5 stars2.83$15.17 149.0%6Short Interest ↑Analyst RevisionGap Up0.28%FULCFulcrum Therapeutics$7.59+3.3%3 of 5 stars3.00$14.67 93.2%6Analyst UpgradeShort Interest ↑News CoverageGap Up0.06%MRNSMarinus Pharmaceuticals$1.354 of 5 stars2.57$13.79 921.2%7Analyst Revision This page (NYSEARCA:XPH) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
